Revenue during the quarter grew 7.93 percent to $13,045 million from $12,087 million in the previous year period. Gross margin for the quarter contracted 529 basis points over the previous year period to 76.35 percent. Total expenses were 76.84 percent of quarterly revenues, up from 72.22 percent for the same period last year. That has resulted in a contraction of 462 basis points in operating margin to 23.16 percent.

Operating income for the quarter was $3,021 million, compared with $3,358 million in the previous year period.

Ian Read, chairman and chief executive officer, stated, "Our business continues to perform well as demonstrated by the quarter’s financial results. Our Innovative Health business executed strongly behind the latest product launches, and our two recent acquisitions -- Medivation and Anacor -- are providing new near-term opportunities to potentially drive incremental growth for the business as its product pipeline continues to mature. We see this business as highly focused on those therapeutic areas where it is best positioned to deliver value to patients."

For fiscal year 2016, Pfizer Inc. forecasts revenue to be in the range of $52,000 million to $53,000 million. The company expects diluted earnings per share to be in the range of $2.38 to $2.43 on adjusted basis.